In light of these results and given that TACC3 is a potent AURKA coactivator41 that is only partially regulated by this mitotic kinase, we reasoned that if TACC3 is required for AURKA activity in KRAS-driven tumours its depletion would recapitulate the AURKA-inhibition phenotype. The gene discussed is KRAS; the disease is neoplasm.